SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a next-gen biopharma company combining automated, experimental biology with artificial intelligence to discover and develop drugs at scale, today announced ...

Recursion Pharmaceuticals has secured $239 million in new venture capital financing, plus a long-term collaboration deal with Bayer to help boost its pipeline in fibrotic diseases of the lung, heart, ...